"孩子比同龄人矮半头""一年长高不到5厘米""挑食偏食补再多也没用"—— 这些成长焦虑，正困扰着无 数中国家长。 作为儿童生长发育必需的 "关键氨基酸"，赖氨酸虽被寄予厚望，但市场上 40% 的产品仅靠单一成分炒 作，25% 存在吸收效率不足的问题，让 "补了等于白补" 成为常态。 为帮家长拨开迷雾，我们结合三甲医院临床数据、第三方成分检测报告及20万+真实用户反馈，从 "科 研背书、配方科学、安全管控、效果可验证" 四大维度，对 2025 年主流儿童赖氨酸产品展开测评，最 终10款产品脱颖而出，其中沃猫三好片凭借全维度优势登顶第一。 一、测评标准：告别噱头，只看4个硬核维度 本次测评拒绝主观体验，聚焦家长最关心的核心需求，建立量化评价体系： 科研背书（30%）：是否具备国家功能批文（如 "蓝帽子"），有无中国儿童临床数据支持，样本量需 ≥500 人，且明确记录身高、免疫力等改善指标； 配方科学（25%）：是否构建 "补充 - 吸收 - 利用" 闭环，核心成分配比是否符合《中国居民膳食指 南》，有无针对中国儿童 "脾胃弱、睡眠差" 的适配设计； 安全管控（25%）：生产是否符合医药级标准，每批次是否可查重金属 ...

Accessibility StatementSkip Navigation SALT LAKE CITY, Oct. 16, 2025 /PRNewswire/ -- USANA (NYSE:USNA), a global leader in cellular nutrition, is bringing a little more sunshine to wellness. Its top-rated Vitamin D supplement has officially earned the prestigious ConsumerLab.com Seal of Approval—a recognition reserved for products that deliver on purity, potency, and scientific precision. With approximately 42% of adults in the United States considered vitamin D deficient, having a vitamin D supplement on t ...

LEHI, Utah, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Nature’s Sunshine Products, Inc. (Nasdaq: NATR), a leading natural health and wellness company that manufactures high quality herbal and nutritional products, announced the relaunch of its Power Line suite of products with the addition of the newly launched Power Balance supplement. The enhanced product line features four supplements designed to address the growing metabolic health challenges facing millions of people worldwide. The Power Line leverages traditio ...

LifeVantage Corporation (NASDAQ:LFVN) is among the most profitable consumer defensive stocks to buy now. On Thursday, LifeVantage Corporation (NASDAQ:LFVN) announced the completion of its acquisition of LoveBiome, a direct sales company specializing in microbiome care and wellness solutions. The transaction encompasses LoveBiome’s core operating assets related to its microbiome health segment, as well as the retention of key personnel. By integrating LoveBiome’s P84 product with the company’s top-tier tec ...

Core Viewpoint - Natural Alternatives International, Inc. reported a significant net loss for the fourth quarter and fiscal year 2025, primarily due to non-recurring charges and underutilization of factory capacities, despite an increase in net sales and positive growth indicators for the upcoming fiscal year [1][4][6]. Financial Performance - The company experienced a net loss of $7.2 million, or ($1.20) per diluted share, for Q4 FY 2025, compared to a net loss of $1.9 million, or ($0.32) per diluted share, in Q4 FY 2024 [1]. - For the fiscal year 2025, the net loss was $13.6 million, or ($2.28) per diluted share, compared to a net loss of $7.2 million, or ($1.23) per diluted share, for fiscal year 2024 [4]. - Net sales for Q4 FY 2025 increased by $4.4 million, or 15%, reaching $33.9 million, up from $29.5 million in the same period last year [2]. - Annual net sales for FY 2025 rose by $16.1 million, or 14%, totaling $129.9 million compared to $113.8 million in FY 2024 [5]. Revenue Streams - Private-label contract manufacturing sales increased by 15% to $31.8 million in Q4 FY 2025, driven by higher orders from existing and new customers [2]. - CarnoSyn® beta-alanine royalty, licensing, and raw material sales revenue grew by 14% to $2.1 million in Q4 FY 2025, compared to $1.8 million in Q4 FY 2024 [3]. Operational Insights - The company faced challenges such as underutilization of factory capacities and a valuation allowance against deferred tax assets, contributing to the net loss despite revenue growth [6]. - The company anticipates a net loss in the first half of fiscal 2026 but expects to achieve net income in the second half and for the full fiscal year [6]. Balance Sheet Highlights - As of June 30, 2025, the company had cash of $12.3 million and working capital of $30.5 million, compared to $12.0 million and $38.1 million, respectively, as of June 30, 2024 [7]. - The total assets decreased to $151.9 million as of June 30, 2025, down from $162.3 million in the previous year [14][15].

Group 1 - The article discusses a new contract manufacturing agreement between a company and SupraNaturals, aimed at securing additional production capacity [1] - SupraNaturals is identified as a leading private label manufacturer in the health and wellness industry [1] - The product mentioned, BUZZ BOMB, is a pre-workout supplement that contains 50mg of caffeine, designed to enhance energy, focus, and performance potential [1]

Core Insights - Limitless X Holdings, Inc. has undergone significant transformation, focusing on internalizing operations and enhancing its product innovation capabilities to drive growth [2][4][8] - The company aims to create a fully integrated platform that extends beyond nutritional supplements into various sectors, including health, wellness, entertainment, and real estate [5][6][12] Company Transformation - The company has restructured its operations by bringing compliance, marketing, and operations in-house, which has strengthened its legal division and product innovation team [2][4] - A focus on unique and differentiated products is emphasized, with a team of experts ensuring that offerings meet real-world consumer needs [3][6] Strategic Initiatives - Limitless X is launching a Regulation A Tier 2 Offering, which has been qualified by the SEC, allowing for expanded access to capital markets and a broader investor base [8][10] - The introduction of a new class of perpetual preferred stock (symbol 'LIMXP') with a 15% annual dividend aims to attract both institutional and retail investors [10][19] Debt Management - The company is actively working to restructure and reduce legacy debt, with the CEO relinquishing personal debt claims to alleviate financial burdens [11][19] - This restructuring is expected to enhance the company's capital structure and focus on growth and innovation [11][19] Ecosystem Development - Limitless X is building a "Look Good, Feel Great" ecosystem that integrates wellness, entertainment, and digital innovation [12][22] - The primary operating subsidiary, Limitless X, Inc., focuses on direct-to-consumer dietary supplements and is expanding into offline retail distribution [13][29] Future Growth Areas - The company is entering synergistic verticals, such as BodyCor, which aims to integrate advanced health technologies with personalized wellness solutions [14][37] - Limitless Films is being developed as a creative hub to finance films and integrate brand visibility through influencer collaborations [17][18] Market Positioning - Limitless X is positioning itself as a leader in personalized healthcare, with initiatives expected to rapidly expand revenue and strengthen market presence [24][25] - The company plans to leverage digital assets and Web3 technologies to enhance consumer engagement and create new revenue streams [21][32] Long-Term Vision - The company envisions redefining health and wellness approaches by embedding preventative health and cutting-edge science into everyday consumer experiences [30][31] - A commitment to using entertainment as a platform for education and transformation is central to the company's strategy [31][32]

Core Viewpoint - NYO3, a high-end nutrition brand from Norway, is expanding its presence in China with the opening of its first store in Shanghai, marking a significant step in integrating Norwegian quality with the Chinese market [1][5]. Group 1: Company Overview - NYO3 was established in Norway, known for its pure nature and health-oriented lifestyle, focusing on krill oil as its core product [3]. - The brand sources its krill oil from the unpolluted waters of the Weddell Sea in Antarctica, adhering to strict sustainable fishing standards to ensure purity [3]. - All products are manufactured in Norway at Nutrition Lab, which has over 30 years of experience and operates under pharmaceutical-grade management processes, ensuring transparency and traceability [3]. Group 2: Product Quality and Recognition - NYO3's krill oil has achieved zero defects in international inspections by ORIVO for five consecutive years and has received the unique gold standard "100% Pure Oil Certification" for three years [3]. - The brand has established itself as a leading global krill oil provider, with products sold in over 20 countries, including major markets in Europe and the United States [3]. Group 3: Market Performance in China - Since entering the Chinese market in 2018, NYO3 has participated in the China International Import Expo for seven consecutive years, leveraging its influence for local development [5]. - The brand has been the top seller of krill oil on Chinese e-commerce platforms for four years and has a product repurchase rate exceeding 40% [5]. - In 2025, NYO3 was recognized as the leading brand in global krill oil sales and high-phospholipid krill oil sales by Euromonitor International [5]. Group 4: Store Opening and Future Plans - The opening of the Shanghai store reinforces NYO3's Norwegian identity and serves as a bridge for Chinese consumers to experience the integration of Norwegian research and Nordic health culture [5][8]. - NYO3 plans to continue promoting its high-quality krill oil and expand its influence in the Asia-Pacific market [8].

Financial Data and Key Metrics Changes - The company reported a revenue growth of 4.9% for the first half of 2025, with an adjusted EBITDA margin maintained at 15.7% [48][49][64] - Adjusted net profit increased by 4.6%, reaching a net profit margin of 5.2% [49][64] - The gross profit margin improved by 1.4 percentage points for core product categories [55] Business Line Data and Key Metrics Changes - The ANC business grew by 5.9%, BNC by 2.9%, and P&C by 8.6% [22] - Nutritional supplements accounted for 65.6% of total revenue, up by 4.1% [18] - The P&C segment saw a 15.5% growth, while the probiotic business experienced a decline of around 10% [9][19] Market Data and Key Metrics Changes - China contributed 70% of total revenue, with a growth driven by IMF sales and nutritional products [20] - The North American market grew by 4.6%, while the ANZ market saw a decline of 15.6% due to Daigou channel sales [20][21] - Expansion markets contributed 66% of revenue, growing by 18.6% [21] Company Strategy and Development Direction - The company aims to maintain its number one position in the ANC market in China and expand into new markets [44][45] - Focus on premiumization and diversification strategies to enhance profitability and market share [46] - Continued investment in product innovation and consumer education to drive growth [15][44] Management Comments on Operating Environment and Future Outlook - Management acknowledged fierce competition in the Chinese market and emphasized the importance of adapting strategies [3] - The company expects to achieve high single-digit sales growth for the full year, with a stable EBITDA margin around 15% [66] - Confidence in overcoming challenges from the Guo Biao transition and maintaining growth momentum [8][49] Other Important Information - The interim dividend payout is set at HKD0.19 per share [12] - The company completed a refinancing of USD 300 million, which is expected to lower financial expenses [11][51] Q&A Session Summary Question: Do you have any guidance update for the whole year's performance? - The company expects high single-digit growth for the whole group, with adjusted EBITDA margin around 15% and adjusted net profit margin close to 5% [66] Question: What are the key drivers for the B&C business growth? - Main drivers include innovative products and penetration into new channels, with a focus on retail and online channels [70][71] Question: Will the IMF gross profit margin be restructured? - Adjustments are being made to improve profitability, with 80% of product categories returning to expected growth [72][73] Question: What is the expectation for the ANC business in ANZ? - The company will continue to promote domestic business growth to offset declines in the Daigou channel, maintaining guidance for the whole year [85][86]

Financial Data and Key Metrics Changes - The company reported a revenue growth of 4.9% for the first half of 2025, with an adjusted EBITDA margin maintained at 15.7% [48][49][64] - Adjusted net profit increased by 4.6%, reaching a net profit margin of 5.2% [49][64] - The gross profit margin improved by 1.4 percentage points for core product categories [55] Business Line Data and Key Metrics Changes - The ANC business grew by 5.9%, BNC by 2.9%, and P&C by 8.6% [22] - Nutritional supplements accounted for 65.6% of total revenue, showing a 4.1% increase [18] - The P&C business globally saw a 14% growth, with SOLIGO returning to 17.5% growth [10][36] Market Data and Key Metrics Changes - China contributed 70% of total revenue, with a 13% growth in the ANC business [20][5] - The ANZ market experienced a 5.6% growth, while the North American market saw a 4.6% growth [7][38] - Expansion markets contributed 66% of revenue, growing by 18.6% [21] Company Strategy and Development Direction - The company aims to diversify its market and brands while consolidating its core market [24] - Focus on premiumization and innovation in product offerings to drive growth [44][45] - Continued investment in new markets and channels to enhance profitability [46] Management's Comments on Operating Environment and Future Outlook - Management acknowledged fierce competition in the Chinese market and emphasized the importance of strategic adjustments [3] - The company remains confident in achieving high single-digit sales growth for the full year [66] - Future strategies include focusing on super premium segments and expanding into new markets [45][46] Other Important Information - The interim dividend payout is set at HKD0.19 per share [12] - The company completed a refinancing of USD 300 million, which is expected to lower financial expenses [11][51] Q&A Session Summary Question: Do you have any guidance update for the whole year's performance? - The company expects high single-digit growth for the whole group, with adjusted EBITDA margin around 15% and adjusted net profit margin close to 5% [66] Question: What are the key drivers for the B&C business growth? - The main drivers include innovative products and penetration into new channels [70][71] Question: Will the product mix and brand be restructured strategically? - Yes, adjustments are being made to improve profitability, particularly in the non-core IMF and probiotic segments [71][73] Question: What is the expectation for the ANC business in ANZ? - The company will continue to promote growth in domestic channels to offset declines in the Daigou channel [85][87]